<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02244658</url>
  </required_header>
  <id_info>
    <org_study_id>RhTPO-AML thrombocytopenia</org_study_id>
    <nct_id>NCT02244658</nct_id>
  </id_info>
  <brief_title>Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia</brief_title>
  <official_title>Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia: a Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy-related myelosuppression usually occurs in AML patients, which induces severe&#xD;
      thrombocytopenia and haemorrhage, a leading cause of death. This clinical trial aims at&#xD;
      evaluating efficacy and safety of rhTPO in management of chemotherapy-induced&#xD;
      thrombocytopenia in acute myelocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are undertaking a parallel group, multicentre, randomized controlled trial&#xD;
      of 80 adults with chemotherapy-induced thrombocytopenia from 8 medical centers in China. AML&#xD;
      patients with PLT count &lt;30×10^9/L during the previous cycle of chemotherapy are randomized&#xD;
      into two groups that one receives rhTPO at 1.0μg/kg·d subcutaneously for 7~14 consecutive&#xD;
      days and the other receives no rhTPO or other thrombopoietic factor. Platelet count, bleeding&#xD;
      and other symptoms were evaluated before and after treatment. Adverse events are also&#xD;
      recorded throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of platelet response</measure>
    <time_frame>21 days since the first administration</time_frame>
    <description>days that PLT count rebound to 30×10^9/L, 50×10^9/L and 100×10^9/L, respectively, from the minimal level after the very cycle of chemotherapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Antineoplastic Adverse Reaction</condition>
  <condition>Thrombocytopenia</condition>
  <condition>Acute Myelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>rhTPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no thrombopoietic agents</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhTPO</intervention_name>
    <description>rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days</description>
    <arm_group_label>rhTPO</arm_group_label>
    <other_name>TPIAO</other_name>
    <other_name>S20050048/49 (SFDA, China)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AML patients with PLT count &lt;30×10^9/L during the previous cycle of chemotherapy to&#xD;
             minimize the risk of clinically significant bleeding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergic history to biological agents; history of thrombotic or hemorrhagic diseases;&#xD;
             M3 or M7 subtype; pregnancy; hypertension; cardiovascular disease; diabetes; liver and&#xD;
             kidney function impairment;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming Hou</last_name>
    <email>houming@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Hou</last_name>
      <email>houming@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Ming Hou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>September 13, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Ming Hou</investigator_full_name>
    <investigator_title>Professor and Director</investigator_title>
  </responsible_party>
  <keyword>chemotherapy-induced thrombocytopenia</keyword>
  <keyword>recombinant human thrombopoietin</keyword>
  <keyword>acute myelocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

